You are here

  • Home
  • Archive
  • Volume 20, Issue 6
  • At 5 years, transcatheter aortic valve replacement had similar rates of mortality and stroke as surgical aortic valve replacement in high-risk patients

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
At 5 years, transcatheter aortic valve replacement had similar rates of mortality and stroke as surgical aortic valve replacement in high-risk patients
  1. Michael J Reardon1,
  2. Neal S Kleiman2
  1. 1 Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA;
  2. 2 Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA
  1. Correspondence to : Dr Michael J Reardon, Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin Street, Suite 1401, Houston, TX 7703, USA; mreardon{at}houstonmethodist.org

https://doi.org/10.1136/ebmed-2015-110216

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Kapadia SR, Leon MB, Makkar RR, et al., PARTNER trial investigators. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015;385:2485–91 and Mack MJ, Leon MB, Smith CR, et al., PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER1): a randomised controlled trial. Lancet 2015;385:2477–84.OpenUrlCrossRefPubMed

    Context

    When calcific aortic stenosis is associated with symptoms, particularly congestive heart failure, it is also associated with a risk of death when not corrected surgically. Unfortunately, the frequency of the disease increases with age and patients who are most likely to have it are those who are at highest risk for open cardiac surgery. Transcatheter aortic valve replacement (TAVR) is an emerging treatment that is considerably less invasive than surgical aortic valve replacement (SAVR). The PARTNER investigators compared TAVR to conservative medical therapy in patients who were not candidates for SAVR (Kapadia and colleagues) and compared TAVR to SAVR in patients who were at high risk for SAVR (Mack and colleagues).

    Methods

    Two studies were performed as part of the PARTNER programme. Inclusion criteria were identical with the exception of perceived surgical risk. In Kapadia and colleagues study, two cardiovascular surgeons and an interventional cardiologist had to agree that …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.